AustCancer subsidiary signs distribution deal

By Renate Krelle
Tuesday, 06 July, 2004

ACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.

Under the deal, wholesale drug cooperative Rochester Drug Cooperative will stock revisys in more than eight hundred community retail pharmacies long-term care pharmacies and home health care stores in New York State, Pennsylvania and New Jersey.

Related News

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...

Global study finds 250 genes linked to OCD

Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...

Content from other channels on our network

Increasing sensor life in harsh conditions

ABB receives EPD status for gearless mill drive ring motor

Enabling OT continuous monitoring

Central Coast Council completes first remote sewer inspection

Ghost Bat a major milestone for local defence manufacturing

Medicare chronic wound care scheme set to benefit 20,000/year

Urinary incontinence and cardiovascular disease risk in women

Pharmacist distraction during dispensing — extent and sources

Ambulance ramping — its "very real potential human consequences"

Could this game wave goodbye to nerve pain?

Victorian home demonstrates grid resilience solution

Australian-made green metals get $19.8m investment

Why grid orchestration must be Australia's next energy imperative

Recycled water to keep Victorian sporting grounds green

Productivity Summit announcement welcomed

All content Copyright © 2025 Westwick-Farrow Pty Ltd